Evidence map›Paper›PMID 41929072›Full record

ArticlebioRxiv : the preprint server for biology2026

Mucin-binding protein shuttles enable delivery of brain-targeted therapeutics.

Sophia M Shi, Gabrielle S Tender, Jian Xiong, Josephine K Buff, Hannah I Park, Justin H Mendiola, Edward N Wilson, Monther Abu-Remaileh, Carolyn R Bertozzi, Tony Wyss-Coray

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Sophia M ShiDepartment of Chemistry, Stanford University, Stanford, CA, USA.ORCID 0000-0001-6935-1034
Gabrielle S TenderDepartment of Chemistry, Stanford University, Stanford, CA, USA.
Jian XiongStanford Chemistry, Engineering & Medicine for Human Health (ChEM-H), Stanford University, Stanford, CA, USA.
Josephine K BuffDepartment of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, USA.
Hannah I ParkDepartment of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, USA.
Justin H MendiolaDepartment of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, USA.
Edward N WilsonDepartment of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, USA.
Monther Abu-RemailehStanford Chemistry, Engineering & Medicine for Human Health (ChEM-H), Stanford University, Stanford, CA, USA.
Carolyn R BertozziDepartment of Chemistry, Stanford University, Stanford, CA, USA.
Tony Wyss-CorayStanford Chemistry, Engineering & Medicine for Human Health (ChEM-H), Stanford University, Stanford, CA, USA.

Funding

Investigating the Surface GlycoproteomeR01CA200423 · NCI · STANFORD UNIVERSITY · PI Carolyn Bertozzi · 2015 to 2026
$3.8M
Targeting CD22 to Restore Brain Homeostasis in Alzheimer's DiseaseRF1AG064897 · NIA · STANFORD UNIVERSITY · PI WYSS-CORAY, TONY · 2019 to 2019
$2.9M
Molecular signature of parabiosisR01AG072255 · NIA · STANFORD UNIVERSITY · PI WYSS-CORAY, TONY · 2021 to 2025
$2.4M
NCI NIH HHS R01 CA200423NIA NIH HHS R01 AG072255NIA NIH HHS RF1 AG064897
6 · The paper itself

Abstract

The blood-brain barrier (BBB) poses a major obstacle to the delivery of therapeutics into the central nervous system (CNS) due to its highly restrictive permeability. Here, we introduce glycan-targeted delivery vehicles, or GlycoShuttles, that traverse the BBB by harnessing the cerebrovascular glycocalyx, a carbohydrate-rich layer lining the BBB lumen. We discover that mucin-domain glycoproteins within this structure serve as novel entry portals for brain delivery and engineer mucin-binding protein shuttles that enable efficient transport of diverse molecular cargo across the BBB into multiple key brain cell types. This modular platform facilitates enhanced brain delivery of a variety of payloads, including antibodies and lysosomal proteins, and demonstrates therapeutic efficacy in mouse models of dementia. Our findings establish mucin-targeted GlycoShuttles as a versatile platform for noninvasive brain delivery of therapeutics, opening new avenues for the treatment of CNS diseases.

Identifiers

PMID41929072
PMCPMC13041825

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.